Clinical outcomes of nicorandil administration in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials

Table 3 Sensitivity analysis of the incidences of MACEs after 1-by-1 exclusion of each individual study

Study removed each time	Statistics after one study removed			Heterogeneity
Study removed each time	OR	95% CI	P	Tau²	I² (%)	P
No study removed	0.42	0.27–0.64	< 0.001	0.21	52	0.03
Chen 2015 [6]	0.41	0.26–0.65	< 0.001	0.24	57	0.02
Chen 2020 [23]	0.42	0.26–0.67	< 0.001	0.24	56	0.02
Feng 2019 [5]	0.42	0.26–0.68	< 0.001	0.23	55	0.02
Ishii 2005 [11]	0.37	0.21–0.64	< 0.001	0.35	57	0.02
Kitakaze 2007 [13]	0.37	0.25–0.54	< 0.001	0.05	16	0.30
Lee 2008 [14]	0.40	0.25–0.63	< 0.001	0.23	57	0.02
Ono 2004 [17]	0.43	0.27–0.68	< 0.001	0.22	54	0.03
Ota 2006 [18]	0.44	0.28–0.69	< 0.001	0.21	53	0.03
Pi 2019 [19]	0.50	0.34–0.74	< 0.001	0.10	34	0.15
Qi 2018 [20]	0.43	0.28–0.67	< 0.001	0.20	53	0.03
Wang 2020 [24]	0.42	0.27–0.64	< 0.001	0.21	52	0.03

CI confidence interval, MACE major adverse cardiovascular events, OR odds ratio

ISSN: 1471-2261